Comparative Pharmacology
Head-to-head clinical analysis: MANGANESE CHLORIDE IN PLASTIC CONTAINER versus MVC PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MANGANESE CHLORIDE IN PLASTIC CONTAINER versus MVC PLUS.
MANGANESE CHLORIDE IN PLASTIC CONTAINER vs MVC PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Manganese chloride dissociates to provide manganese (Mn²⁺), a cofactor for enzymatic reactions including superoxide dismutase (mitochondrial), pyruvate carboxylase, and arginase. It participates in carbohydrate and lipid metabolism, bone development, and antioxidant defense.
MVC PLUS is a fixed-dose combination of maraviroc, a CCR5 co-receptor antagonist, and lamivudine, a nucleoside reverse transcriptase inhibitor. Maraviroc binds to CCR5 on CD4+ T cells blocking HIV-1 entry; lamivudine inhibits HIV reverse transcriptase via competitive inhibition and chain termination.
Intravenous, 0.1 to 0.4 mg/mL as additive to parenteral nutrition, typically 1 to 5 mg per day depending on clinical status and serum levels. Frequent monitoring of manganese levels recommended.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 12-40 days (varies with body stores and nutritional status; prolonged in hepatic impairment due to reduced biliary clearance).
Terminal elimination half-life: 12-18 hours (mean 14 hours). Clinically, this supports twice-daily dosing with steady-state achieved in ~3 days.
Renal (biliary/fecal minimal): ~90% of absorbed manganese excreted in bile into feces, with <5% renal excretion; in parenteral administration, renal elimination is negligible as manganese is predominantly cleared via hepatobiliary system.
Renal: ~70% unchanged; Fecal: ~25%; Biliary: <5%
Category C
Category C
Mineral Supplement
Multivitamin/Mineral Supplement